CC
NBIX icon

Cipher Capital’s Neurocrine Biosciences NBIX Stock Holding History

Cipher Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$232K Sell
1,680
-8,523
-84% -$1.16M 0.11% 336
2023
Q4 		$1.34M Buy
10,203
+3,411
+50% +$393K 0.44% 52
2023
Q3 		$764K Buy
+6,792
New +$715K 0.54% 50

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cipher Capital's NBIX Position: Q1 2024 in Review

Cipher Capital reduced its Neurocrine Biosciences (NBIX) stake by 84% in Q1 2024, selling an estimated $1.16M and leaving 1,680 shares worth $232K. The position accounts for 0.11% of the portfolio, ranked #336.

Cipher Capital first reported a position in NBIX in Q3 2023 and has held it in 3 quarters since. The position peaked at $1.34M in Q4 2023. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Cipher Capital held 1,680 shares of Neurocrine Biosciences worth $232K as of Q1 2024.
  • Cipher Capital sold 8,523 Neurocrine Biosciences shares in Q1 2024, an estimated $1.16M.
  • Neurocrine Biosciences made up 0.11% of Cipher Capital's portfolio in Q1 2024, its #336 holding.
  • Cipher Capital first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 3 quarters since.
  • Cipher Capital's Neurocrine Biosciences position peaked at $1.34M in Q4 2023.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.